Gil A, Lavilla P, Gonzalez A, Valencia ME, Dupla JM, Vazquez JJ; International Conference on AIDS.

Int Conf AIDS. 1989 Jun 4-9; 5: 553 (abstract no. M.C.P.71).

Hospital La Paz, Madrid, Spain

PURPOSE OF THE STUDY: To assess the efficacy and safety of Fluconazole in the treatment of esophageal candidiasis in AIDS patients. RESULTS: 36 patients (25 male and 11 female) were included. Mean age was 28 years (range: 19-). There were 30 IV drug abusers, 5 homosexuals and 1 heterosexual contact. In all cases, esophageal candidiasis was confirmed by endoscopy, biopsy and/or culture. Therapeutic regime: 100 mg (1st day) followed by 100 mg daily p.o. for 4 weeks. Endoscopy control was carried out at the end of the treatment. A follow up visit 1 month after treatment was scheduled. Careful surveillance was performed in all patients. Therapeutic evaluation was performed in 33 patients, although only 31 completed treatment. The study was carried out over a ten month period (February-December 1988). During this time 8 patients died; 4 in the protocol stage and a further 4 after completing treatment, all of these due to other opportunistic infections. Clinical and mycological cure was achieved in all patients; in most, clinical picture resolved within a week. In 2 patients an esophageal relapse occurred 1 month after treatment. Re-treatment with Fluconazole achieved cure again. In a further 9 patients asymptomatic oropharyngeal fungal colonization was observed. No gastrointestinal, hematological, renal or cutaneous toxicity was observed. Elevations of liver enzymes: discrete (15 patients), moderate (1 patient) and severe (1 patient), the latter leading to drug discontinuation, were recorded. Increases of alkaline phosphatase without hyperbilirubinemia (29%) was the most commonly observed adverse effect; however, it has to be taken into account that most patients had coexisting opportunistic infections and/or received potentially hepatotoxic concomitant therapy. CONCLUSIONS: 1) Fluconazole has shown to be an effective and safe treatment of esophageal candidiasis in AIDS patients. 2) A shorter treatment may be efficacious in this condition. 3) An effective prophylactic regime with Fluconazole in these patients would be most desirable.

Publication Types:

• Meeting Abstracts

Keywords:

• Acquired Immunodeficiency Syndrome
• Candidiasis
• Esophageal Diseases
• Esophagitis
• Female
• Fluconazole
• Humans
• Male
• Opportunistic Infections
• therapy

Other ID:

• 00287689

UI: 102178778

From Meeting Abstracts